Early fibrinogen degradation coagulopathy: A predictive factor of parenchymal hematomas in cerebral rt-PA thrombolysis

Journal of the Neurological Sciences

Volumn 351, Issue 1-2, 2015, Pages 109-114

  Sun, Xuhong ^a,b   Berthiller, Julien ^a,c   Trouillas, Paul ^a   Derex, Laurent ^a   Diallo, Laho ^a   Hanss, Michel ^c  

^a UNIVERSITÉ LYON 1   (France)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

Fibrinogen; Fibrinogen degradation products; Hemorrhagic infarcts; Parenchymal hematoma

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; BLOOD CLOTTING FACTOR 13; D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; PLASMINOGEN; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN INFARCTION; COMPARATIVE STUDY; DIABETES MELLITUS; FEMALE; FIBRINOGEN METABOLISM; HEMATOMA; HEMORRHAGIC INFARCT; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PARENCHYMATOUS HEMATOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; ADVERSE EFFECTS; CEREBRAL HEMORRHAGE; CHEMICALLY INDUCED; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRINOLYTIC THERAPY; MIDDLE AGED; PROGNOSIS;

AGED; BRAIN INFARCTION; CEREBRAL HEMORRHAGE; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HEMATOMA; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84926408588     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2015.02.048     Document Type: Article

References (37)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
2. W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Davalos, and D. Guidetti Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
3. IST-3 collaborative group The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial Lancet 379 2012 2352 2363
4. N. Wahlgren, N. Ahmed, A. Dávalos, G.A. Ford, M. Grond, and W. Hacke Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study Lancet 369 2007 275 282
5. M. Kaste Do not wait, act now Stroke 38 2007 3119 3120
6. D.E. Levy, T.G. Brott, E.C. Haley, J.R. Marler, G.L. Sheppard, and W. Barsan Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke Stroke 25 1994 291 297
7. The NINDS t-PA Stroke Study Group Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke Stroke 28 1997 2109 2118
8. W. Hacke, M. Kaste, C. Fieschi, R. von Kummer, A. Davalos, and D. Meier Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Lancet 352 1998 1245 1251
9. M. Pessin, G.J. del Zoppo, and C. Estol Thrombolytic agents in the treatment of stroke Clin Neuropharmacol 13 1990 271 289
10. P. Trouillas, and Von Kummer Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke Stroke 37 2006 556 561
11. V. Larrue, R. Von Kummer, G. Del Zoppo, and E. Bluhmki Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study Stroke 28 1997 957 960
12. V. Larrue, R. von Kummer, A. Müller, and E. Bluhmki Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European-Australasian Acute Stoke Study (ECASS II) Stroke 32 2001 438 441
13. M. Fiorelli, S. Bastaniello, R. Von Kummer, G. Del Zoppo, V. Larrue, and E. Lesaffre Hemorrhagic transformation within 36 hours of a cerebral infarct. Relationship with early clinical deterioration and 3-month outcome in the European Cooperative Stroke Study I (ECASS I) cohort Stroke 30 1999 2280 2284
14. J.M. Olivot, M. Mlynash, V.N. Thijs, A. Purushotam, S. Kemp, and M.G. Lansberg Geography, structure, and evolution of diffusion and perfusion lesions in Diffusion and perfusion imaging Evaluation For Understanding Stroke Evolution (DEFUSE) Stroke 40 10 2009 Oct. 3245 3251
15. D.C. Alsop, E. Makovetskaya, S. Kumar, M. Selim, and G. Schlaug Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke Stroke 36 2005 746 750
16. L. Derex, M. Hermier, P. Adeleine, J.B. Pialat, M. Wiart, and Y. Berthezene Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator J Neurol Neurosurg Psychiatry 76 2005 70 75
17. A.H. Cho, J.S. Kim, S.J. Kim, S.C. Yun, C.G. Choi, and H.R. Kim Focal fluid-attenuated inversion recovery hyperintensity within acute diffusion-weighted imaging lesions is associated with symptomatic intracerebral hemorrhage after thrombolysis Stroke 39 2008 3424 3426
18. L. Dorado, M. Millán, N. Pérez de la Ossa, C. Guerrero, M. Gomis, and A. Aleu Time to recanalization and risk of symptomatic intracerebral haemorrhage in patients treated with intravenous thrombolysis Eur J Neurol 19 2012 1251 1255
19. M.G. Lansberg, V.N. Thijs, R. Bammer, S. Kemp, C.A. Wijman, and M.P. Marks Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke Stroke 38 2007 2275 2278
20. C.A. Cronin, N. Shah, T. Morovati, L.D. Hermann, and K.N. Sheth No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in Patients with European Cooperative Acute Stroke Study (ECASS) Exclusion Criteria Stroke 43 2012 1684 1686
21. D. Strbian, S. Engelter, P. Michel, A. Meretoja, L. Sekoranja, and F.J. Ahlelm Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score Ann Neurol 71 2012 634 641
22. M. Mazya, J.A. Egido, G.A. Ford, K.R. Lees, R. Mikukik, and D. Toni Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score Stroke 43 2012 1524 1531
23. A.M. Demchuk, L.B. Morgenstern, D.W. Krieger, T. Linda Chi, W. Hu, and T.H. Wein Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke Stroke 30 1999 34 39
24. B. Matosevic, M. Knoflach, Ph. Werner, R. Pechlaner, A. Zangerle, and M. Ruecker Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis Neurology 80 2013 1216 1224
25. K. Fassbender, C.E. Dempfle, O. Mielke, M. Daffertshofer, C. Eschenfelder, and M. Dollman Changes in coagulation and fibrinolysis in markers in acute ischemic stroke treated with recombinant tissue plasminogen activator Stroke 30 1999 2101 2104
26. D. Tanne, S.E. Kasner, A.M. Demchuk, N. Koren-Morag, M. Hanson, and M. Grond Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey Circulation 105 2002 1679 1685
27. P. Trouillas, L. Derex, F. Philippeau, N. Nighoghossian, J. Honnorat, and M. Hanss Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases Stroke 35 2004 1323 1328
28. P. Trouillas, N. Nighoghossian, J.C. Getenet, G. Riche, P. Neuschwander, and J.C. Froment Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke Stroke 27 1996 882 890
29. G. Thomalla, J. Sobesky, M. Köhrmann, J.B. Fiebach, J. Fiehller, and O. Zaro Weber Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours Stroke 3 2007 313 318
30. W. Nieuwenhuizen Plasma assays for derivatives of fibrin and fibrinogen, based on monoclonal antibodies Fibrinolysis 2 1988 1 5
31. D. Collen, H. Bounameaux, F. De Cock, F. De Cock, H.R. Lijnen, and M. Verstraete Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with myocardial infarction Circulation 73 1986 563 569
32. M.M. Wintrobe, G.R. Lee, D.R. Boggs, T.C. Bithell, J. Foerster, and J.W. Athens Clinical hematology 8th ed. 1981 Lea and Febiger Philadelphia, PA 434
33. K. Stangl, M. Laule, B. Tenckhoff, V. Stangl, V. Gliech, and P. Dübel Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction Am J Cardiol 81 1998 841 847
34. S. Szabo, R. Letsch, R. Ehlers, T. Walter, S. Kazmaier, and U. Helber Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase Thromb Res 106 2002 113 119
35. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, F. Van De Werf, J. Adgey, D. Ardissino, P.W. Armstrong, P. Aylward, and G. Barbash Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial Lancet 354 1999 716 722
36. M. Parsons, N. Spratt, A. Bivard, B. Campbell, K. Chung, and F. Miteff A randomized trial of tenecteplase versus alteplase for acute ischemic stroke N Engl J Med 366 2012 1099 1107
37. M. Ribo, J. Montaner, C.A. Molina, J.F. Arenillas, E. Sanramarina, and M. Quintana Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator Stroke 35 2004 2123 2127